Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient

Zhe Huang,Yongchang Zhang
DOI: https://doi.org/10.1111/1759-7714.14818
IF: 3.223
2023-02-08
Thoracic Cancer
Abstract:Small cell lung cancer patients presenting with metastasis of the iris are rare. Here, we report an extensive stage small cell lung cancer patient who presented with iris metastasis in the right eye and metastasis in the left adrenal gland as disease progression to first‐line chemotherapy plus atezolizumab. The patient was subsequently treated with irinotecan combined with anlotinib and atezolizumab, and a dramatic response was obtained not only for left adrenal gland metastasis but for iris metastasis. Small cell lung cancer (SCLC) is an aggressive malignancy associated with poor prognosis. Metastasis to sites outside the chest at the time of initial diagnosis, such as bone, brain, and liver metastasis have been found in most SCLC patients. Iris metastases from SCLC have rarely been previously reported, and often cause eye pain and blindness in patients. Here, we report a patient with SCLC who presented with iris metastasis in the right eye and metastasis in the left adrenal gland due to disease progression on first‐line therapy, which subsequently caused pain and blindness in the right eye. The patient was treated with second‐line irinotecan combined with anlotinib and atezolizumab and did not receive any local treatment in the right eye. After only one cycle of treatment, the iris metastases in the right eye were smaller than before, and the visual acuity in the right eye recovered. At the same time, her left adrenal metastases were also significantly smaller than before. Our case suggests that systemic therapy with effective treatment options can similarly improve iris metastases in patients.
oncology,respiratory system
What problem does this paper attempt to address?